In 2020, the US Food and Drug Administration and the European Medicines Agency approved the use of bempedoic acid in adults with hypercholesterolemia. Bempedoic acid competitively inhibits ATP-citrate lyase in the pathway responsible for cholesterol synthesis. This results in decreased cholesterol synthesis by the liver, upregulation of LDL receptors, and subsequent clearance of circulating LDL. Analyses suggest that bempedoic acid may reduce LDL cholesterol by approximately 23% compared with placebo. Bempedoic acid may be considered for patients who cannot use or tolerate other LDL cholesterol–lowering approaches or for whom other therapies have been inadequately effective.
Preliminary data were promising for the use of lipoprotein lipase inhibitors for management of dyslipidemia, but evidence from clinical trials raised safety concerns.
Gene editing using CRISPR-associated protein 9 techniques have shown some evidence of efficacy in preclinical studies, but to date, no compounds are under investigation in humans.
Learn more about type 2 diabetes.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Anne L. Peters, Romesh Khardori. Fast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape - Apr 21, 2023.